- Home
- HIW vs KNSA Comparison
HIW vs KNSA Comparison
Compare HIW & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HIW | KNSA |
|---|---|---|
| Founded | 1978 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 3.4B |
| IPO Year | 1995 | 2018 |
Fundamental Metrics
Financial Performance| Metric | HIW | KNSA |
|---|---|---|
| Price | $21.56 | $46.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $29.50 | ★ $55.29 |
| AVG Volume (30 Days) | ★ 1.7M | 574.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 9.17% | N/A |
| EPS Growth | 54.26 | ★ 225.00 |
| EPS | ★ 1.45 | 0.75 |
| Revenue | ★ $806,112,000.00 | $677,564,000.00 |
| Revenue This Year | $6.91 | $38.01 |
| Revenue Next Year | $3.49 | $17.42 |
| P/E Ratio | ★ $15.05 | $61.77 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $21.24 | $18.26 |
| 52 Week High | $32.76 | $49.12 |
Technical Indicators
Market Signals| Indicator | HIW | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 32.72 | 55.14 |
| Support Level | N/A | $40.47 |
| Resistance Level | $23.68 | $46.48 |
| Average True Range (ATR) | 0.67 | 2.16 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 12.09 | 64.75 |
Price Performance
Historical ComparisonAbout HIW Highwoods Properties Inc.
Highwoods Properties Inc is a fully integrated office REIT that owns, develops, acquires, leases, and manages office properties mainly in the best business districts of Atlanta, Charlotte, Dallas, Nashville, Orlando, Raleigh, Richmond, and Tampa. Its principal business is the operation, acquisition, and development of rental office properties, with no material inter-segment transactions. The Company evaluates performance by geographic location, and the operating results by geographic grouping are regularly reviewed by the chief operating decision maker. The core portfolio consists mainly of office properties in its key markets, with the majority of revenue derived from its Raleigh properties.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.